Jair Arciniegas

Mr. Jair Arciniegas

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2024 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
ARA. C. Rubio
A. C. Rubio
JAJair Arciniegas
Jair Arciniegas
JBJ. E. Bolanos-Lopez
J. E. Bolanos-Lopez
FGF. J. Gonzalez
F. J. Gonzalez
DGD. Gomez
D. Gomez
JRJuan Manuel Reyes
Juan Manuel Reyes
Background: To describe the epidemiology and clinical characteristics of migraine and the status of treatment in Colombia. Additionally, the use of health resources by patients was measured. Methods: This was a non-interventional, retrospective, descriptive study conducted in one Colombian Health Management Organization (HMO) from 2018 to 2022 with a follow-up period of 5 years. Migraine patients were identified using the International Code Disease 10th version G43, and the diagnosis was confirmed by a neurologist. The first recorded migraine diagnosis was defined as the index date. Medical records, claim databases and other electronic databases from the HMO were used to determine the clinical characteristics, treatments, and health care services. Results: A total of 89,227 patients were included in the study. The mean follow-up period was 3.7 years (standard deviation 1.2). Most of them were women (84.9%). Many patients were first seen by a general practitioner (82.6%), and only 8.9% were first seen by a neurologist. The prevalence of migraine during follow-up was between 1.69 and 2.42 patients in 100 HMO affiliates in 2020, the year with the highest prevalence (2.42 [95% CI 2.41–2.44]), and the incidence ranged from 0.032 to 1.72 per 100 patient-year at risk of developing migraine. Hypertension (21.3%), arrythmia (4.1%) and structural heart disease (3.4%) were the most common cardiovascular diseases. The annual mean number of outpatient consultations in 2018 was 1.43 consultations per patient, which decreased to 0.68 in 2022. The most frequent treatments for acute events were nonsteroidal anti-inflammatory drugs (NSAIDs) (range 37-42%) in monotherapy, combinations of analgesics (range 14-35%), and corticosteroids (range 10-15%). Triptans were used in 4% of patients in the first medication record, reaching a maximum of 16% of patients. Among preventive treatments, beta-blockers (24-49%) and antiepileptics (29-41%) were the most common. Conclusion: The prevalence of migraine in Colombia according to health electronic databases was lower than that reported in previous studies conducted in the country. The treatment patterns for acute and preventive treatment of migraine follow the recommendations of different guidelines. Cardiovascular disease is relevant for the management of migraine.

2 August 2015 in Acta Médica Colombiana
Verified
Journal Article
Closed access
DRDiego Rosselli
Diego Rosselli
NCNatalia Castaño
Natalia Castaño
JAJair Arciniegas
Jair Arciniegas
ÁGÁngel A. García
Ángel A. García
ÓMÓscar-Mauricio Muñoz
Óscar-Mauricio Muñoz
CGCarlos Gómez-Restrepo
Carlos Gómez-Restrepo
Objetivo: Determinar la relación de costo-efectividad relativa de las estatinas entre sí en pacientes adultos con dislipidemia con predominio de hipercolesterolemia para la prevención de eventos cardiocerebrovasculares, en Colombia, desde la perspectiva del sistema de salud colombiano. Métodos: Se construyó un modelo de Markov con años de vida ajustados por calidad (AVAC) ganados como desenlace principal, tasa de descuento de 3 % tanto para costos como desenlaces, y cinco años de horizonte temporal. Probabilidades y costos se extrajeron de la literatura y de fuentes oficiales del país, respectivamente. El umbral de costo-efectividad fue tres veces el PIB per cápita de 2012. Se realizaron análisis de sensibilidad univariados, probabilísticos, umbral y curva de aceptabilidad. Resultados: El costo promedio del tratamiento con estatinas para un paciente con dislipidemia en 5 años es de $ 3.472.733.La ganancia en AVAC en rosuvastatina fue mayor con respecto a las otras estatinas, sin embargo, es la estrategia más costosa. La atorvastatina, que resultó segunda, es la más costo-efectiva. Conclusión: La intervención más costo-efectiva para pacientes con dislipidemia con predominio de hipercolesterolemia e indicación de manejo farmacológico con terapia moderada y alta con estatinas en Colombia es la atorvastatina.

1 April 2016 in Revista Colombiana de Psiquiatría
Verified
Journal Article
Closed access
HRHoover Quitian Reyes
Hoover Quitian Reyes
JAJair Arciniegas
Jair Arciniegas
APAdriana Bohórquez Peñaranda
Adriana Bohórquez Peñaranda
CRCarlos Gómez Restrepo
Carlos Gómez Restrepo

1 July 2014 in Investigación & Desarrollo
Verified
Journal Article
Open access
YOYenni Viviana Duque Orozco
Yenni Viviana Duque Orozco
MRMaría Carolina Ortíz Riaga
María Carolina Ortíz Riaga
JAJair Arciniegas
Jair Arciniegas

30 March 2025 in Expert Review of Vaccines
Verified
Journal Article
Open access
JAJair Arciniegas
Jair Arciniegas
JRJuan Manuel Reyes
Juan Manuel Reyes
CMCarlos Fernando Mendoza
Carlos Fernando Mendoza
ICIustina Chirila
Iustina Chirila
MKMoe Hein Kyaw
Moe Hein Kyaw
BYBen Yarnoff
Ben Yarnoff
Using adapted COVID-19 vaccines targeting current variants in circulation is necessary for addressing the dynamic evolution of the SARS-CoV-2 virus and protecting against emerging variants. This study evaluated the impact of various vaccination strategies with an adapted vaccine in Colombia. Using a previously published combined Markov-decision tree model adapted for the Colombia context, this study estimated the outcomes of different vaccination strategies targeting various age and risk groups. The model used age-specific epidemiology, clinical, cost, and quality of life inputs derived from the published literature and national surveillance data. Scenario and sensitivity analyses were conducted to assess uncertainty. Compared to no vaccination, the vaccination strategy targeting older adults aged ≥65 years and the high-risk population was estimated to prevent 306,460 symptomatic cases, 5,200 hospitalizations, 3,381 deaths, and 39,454 lost QALYs, translating to total direct and societal cost savings of USD 70,840,305 and USD 128,918,995, respectively. These gains were further increased by expanding vaccination to additional age groups. Results were most sensitive to parameters for the attack rate and duration of protection. Implementing vaccination strategies targeting a broader age range with an adapted vaccine would result in considerable health and economic benefits in Colombia.

Verified
Journal Article
Open access
PDF file
JAJair Arciniegas
Jair Arciniegas
JRJuan Manuel Reyes
Juan Manuel Reyes
JBJhon Bolaños-López
Jhon Bolaños-López
JSJulia Spinardi
Julia Spinardi
JYJingyan Yang
Jingyan Yang
CMCarlos Fernando Mendoza
Carlos Fernando Mendoza
Studies on the burden of COVID-19 cases in Colombia have focused on specific populations and short timeframes. A retrospective observational study was conducted on adult patients aged 18 diagnosed with COVID-19 who received inpatient and/or outpatient medical care at a large health maintenance organization, to evaluate the burden of COVID-19 cases in Colombia (from March 2020 to January 2023) and associations with demographic and clinical characteristics. COVID-19 cases were identified with ICD-10 codes and confirmed by a laboratory test. The statistical analysis focused on descriptors of the frequency of events. A multivariate regression model was used to identify factors associated with severe conditions and death. Of the 953,661 cases detected, most cases (~79%) were mild or moderate (handled as outpatients). There were 20.1% (N = 191,260) severe cases and 0.9% (N = 8841) critical cases. Most COVID patients were unvaccinated (94.6%) and had, on average, one comorbidity. Hypertension (19.1%), immunocompromised condition (23.8%), mental health conditions (15%), obesity (10.8%), and cancer (11.2%) were the common prevalent comorbidities. The presence of comorbidity increased the risk of severe or critical COVID-19. COVID-19 cases were associated with the lack of vaccination and comorbidities. Effective vaccination strategies are needed to reduce the burden of COVID-19 in Colombia and, considering budgetary constraints, it is advisable to prioritize the elderly or populations with underlying conditions.